KAGOCEL PILLS 12MG
KAGOCEL PILLS 12MG - 20 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
1 pill contains: Kagocel 12 mg
Excipients: Potato starch, Calcium stearate, ludipress (direct compression lactose with the composition: lactose monohydrate, povidone (collidon 30), crospovidone (collidone CL))
Mechanism of action
Kagocel is an antiviral and immunomodulatory drug. Interferon synthesis inductor. The active substance is the sodium salt of the copolymer (1 → 4) -6-0-carboxymethyl-β-D-glucose, (1 → 4) -β-D-glucose and (21 → 24) -2,3,14,15, 21,24, 29,32-octahydroxy-23- (carboxymethoxymethyl) -7,10-dimethyl-4, 13-di (2-propyl) -19,22,26,30,31,3-pentaoxa heptacyclo [18.104.22.168. 05.20.28.08.27.09.18.012.17] dotiaconthus-1,3,5 (28), 6,8 (27), 9 (18), 10, 12 (17), 13,15-decaene.
It causes the formation in the body of the so-called late interferon, which is a mixture of alpha- and beta-interferons with high antiviral activity. Kagocel causes the production of interferon in almost all cell populations involved in the antiviral response of the body: T-and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When ingested with a single dose of Kagocel, the serum interferon titer reaches maximum values after 48 hours. The body’s interferon response to Kagocel administration is characterized by prolonged (up to 4-5 days) circulation of interferon in the bloodstream.The dynamics of accumulation of interferon in the intestines when taking the drug inside does not coincide with the dynamics of circulating interferon titers. In serum, the content of interferon reaches high values only 48 hours after taking Kagocel, while in the intestine the maximum production of interferon is observed already after 4 hours.
Kagocel, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.
- Prevention and treatment of influenza and other acute respiratory viral infections in adults.
- Treatment of influenza and other acute respiratory viral infections in children aged 6 years and older.
- Treatment of herpes in adults.
- Children's age up to 6 years.
- Increased individual sensitivity.
Use during pregnancy and lactation
The drug is contraindicated for use in pregnancy.
Dosage and administration
For the treatment of influenza and SARS - appointed in the first 2 days - 2 tab. 3 times a day, in the next 2 days - 1 tab. 3 times a day. Total for a course of 4 days - 18 tablets.
Prevention of SARS is carried out 7-day cycles: 2 days - 2 tab. Once a day, a break for 5 days. Then the cycle is repeated. The duration of the prophylactic course varies from 1 week to several months.
For the treatment of herpes appoint 2 tab. 3 times a day for 5 days. Total for a course of 5 days - 30 tablets.
For the treatment of influenza and SARS appointed in the first 2 days - 1 tab. 3 times a day, in the next 2 days - 1 tab. 2 times a day. Total for a course of 4 days - 10 tablets.
Possible: allergic reactions.
The greatest effectiveness in the treatment of Kagocel is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For prophylactic purposes, the drug can be used at any time, incl. and immediately after contact with the pathogen.
Kagocel is well combined with other antiviral drugs, immunomodulators and antibiotics.
With the simultaneous use of Kagocel with other antiviral drugs, immunomodulators and antibiotics, an additive effect has been described.
Treatment: in case of accidental overdose, it is recommended to prescribe a heavy drink, induce vomiting.
Store in a dry, dark place at a temperature not exceeding 25 ° C.
Keep out of reach of children.